Access to Ripretinib for People with Previously Treated Metastatic or Inoperable Gastrointestinal Stromal Tumor


Full Title

Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies


This study gives patients with metastatic or inoperable gastrointestinal stromal tumor (GIST) access to the drug ripretinib. GISTs are believed to grow in response to changes (mutations) in specific genes. Ripretinib blocks the signals from the genetic mutations that cause GIST cells to grow. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic or inoperable GIST that continues to grow despite treatment with at least two prior therapies (such as imatinib, sunitinib, and regorafenib).
  • At least 1 week must pass between the completion of prior treatment and entry into the study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ping Chi at 646-888-4166.



Disease Status

Relapsed or Refractory